Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Assess the safety of SAR342434 and Humalog when used in external pumps.
Secondary Objectives:
- Intervals for infusion set changes.
- Incidence of insulin pump alarms for infusion set occlusion.
- Patient observation of infusion set occlusion.
- Adverse events including bruising at the infusion site and injection site reactions.